Shopping Cart
Remove All
Your shopping cart is currently empty
TRK-IN-29 (Compound B31) is a second-generation TRK inhibitor with IC50 values of 9 nM for TRKAG595R, 0.6 nM for TRKAF589L, 18 nM for TRKAG667C, 5 nM for TRKA, and 6 nM for TRKC. It effectively inhibits the phosphorylation of TRKA and demonstrates significant antiproliferative activity against NTRK fusion-positive cells. TRK-IN-29 also exhibits excellent plasma stability and moderate pharmacokinetic properties.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Backorder | Backorder | |
| 50 mg | Inquiry | Backorder | Backorder |
| Description | TRK-IN-29 (Compound B31) is a second-generation TRK inhibitor with IC50 values of 9 nM for TRKAG595R, 0.6 nM for TRKAF589L, 18 nM for TRKAG667C, 5 nM for TRKA, and 6 nM for TRKC. It effectively inhibits the phosphorylation of TRKA and demonstrates significant antiproliferative activity against NTRK fusion-positive cells. TRK-IN-29 also exhibits excellent plasma stability and moderate pharmacokinetic properties. |
| In vitro | TRK-IN-29 exhibits significant antiproliferative activity against Km-12, Ba/F3-TRKA G595R, and Ba/F3-TRKA G667C cells, with IC50 values of 0.3, 4.7, and 9.9 nM, respectively. |
| Formula | C19H17F3N6O |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.